Omnicell, Inc. provides automated pharmacy solutions and medication management services. Its core products include medication dispensing systems, inventory management solutions, and software for pharmacy operations. The company operates primarily in the healthcare sector, focusing on improving medication safety and efficiency in hospitals and pharmacies. Major revenue sources stem from product sales, software subscriptions, and service contracts.
The investment profile of Omnicell is more aligned with balanced investors, given its focus on technology in the healthcare sector and moderate growth potential. The company has shown some revenue decline, indicating a cautious outlook. Its lack of dividends further suggests a focus on reinvestment rather than immediate returns.
| Date | Before | After | Reason |
|---|---|---|---|
| 2026-07-31 | Hold | Sell | Weak momentum and high risk signal sell recommendation. |
| 2026-07-29 | Sell | Hold | Mixed performance; cautious outlook amid revenue decline. |
| 2026-07-21 | Hold | Sell | Weak fundamentals and negative momentum raise concerns. |
| 2026-06-26 | — | Hold | Weak fundamentals and negative momentum raise concerns. |
| Date | Analyst | Action | Target | Price Then |
|---|---|---|---|---|
| 2026-07-31 | KeyBanc | Target Lowered | 70 → 65 | 37.11 |
| 2026-07-31 | Wells Fargo | Target Lowered | 55 → 50 | 37.11 |
| 2026-04-29 | Craig-Hallum | Target Raised | 53 → 55 | 44.4543 |
| 2026-04-28 | KeyBanc | Target Raised | 60 → 70 | 44.31 |
| 2026-03-13 | UBS | Update | — → 60 | 35.1 |
| 2026-02-06 | Piper Sandler | Target Lowered | 63 → 49 | 39.08 |
| 2026-01-16 | UBS | Target Raised | — → 53 | 50.98 |
| 2026-01-07 | KeyBanc | Rating Upgraded | — → 60 | 47.45 |
| 2026-01-05 | Wells Fargo | Target Raised | 43 → 52 | 45.64 |
| 2025-08-11 | Piper Sandler | Target Lowered | — → 55 | 31.1128 |
